Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Subsys vs Fentanyl Citrate Injection
NCT02138396Phase 1Completed
- Sponsor
- Insys Therapeutics
- Start
- Jan 2014
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fentanyl (transdermal patch + oral transmucosal lozenge) in breakthrough cancer pain (BTcP) (2 arms), sponsored by Insys Therapeutics. Primary endpoint: Maximum concentration at 36 hours. Started Jan 2014; status: completed.
02
Drugs
fentanyl (transdermal patch + oral transmucosal lozenge)
03
Conditions
breakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on NCT02138396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02138396.